Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group

Clifford E. Kashtan; Jie Ding; Guido Garosi; Laurence Heidet; Laura Massella; Koichi Nakanishi; Kandai Nozu; Alessandra Renieri; Michelle Rheault; Fang Wang; Oliver Gross

doi:10.1016/j.kint.2017.12.018

Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group

Clifford E. Kashtan, Jie Ding, Guido Garosi, Laurence Heidet, Laura Massella, Koichi Nakanishi, Kandai Nozu, Alessandra Renieri, Michelle Rheault, Fang Wang, Oliver Gross

Pediatrics - Nephrology

Research output: Contribution to journal › Article › peer-review

191 Scopus citations

Abstract

Mutations in the genes COL4A3, COL4A4, and COL4A5 affect the synthesis, assembly, deposition, or function of the collagen IV α345 molecule, the major collagenous constituent of the mature mammalian glomerular basement membrane. These mutations are associated with a spectrum of nephropathy, from microscopic hematuria to progressive renal disease leading to ESRD, and with extrarenal manifestations such as sensorineural deafness and ocular anomalies. The existing nomenclature for these conditions is confusing and can delay institution of appropriate nephroprotective therapy. Herein we propose a new classification of genetic disorders of the collagen IV α345 molecule with the goal of improving renal outcomes through regular monitoring and early treatment.

Original language	English (US)
Pages (from-to)	1045-1051
Number of pages	7
Journal	Kidney international
Volume	93
Issue number	5
DOIs	https://doi.org/10.1016/j.kint.2017.12.018
State	Published - May 2018

Bibliographical note

Funding Information:
The French Alport Registry is supported by the French Association for the Information and Research on Genetic Renal Diseases (AIRG-France), the National database on Rare Diseases (BNDMR; http://www.bndmr.fr ), and the Rare Disease Cohorts (RADICO; http://www.radico.fr/fr/ ) and participates in the ATHENA study sponsored by Regulus Therapeutics.

Funding Information:
The Italian registry of Alport syndrome is supported by Italian Association of Alport Syndrome (ASAL; www.asalonlus.it ) by donations in favor of Graziano and Marco Laurini and the correlated biobank is within the Telethon Network of Genetics Biobanks (TNGB; project no. GTB12001).

Funding Information:
The Alport Syndrome Treatments and Outcomes Registry (ASTOR) is supported by the Alport Syndrome Foundation, the Kenneth and Claudia Silverman Family Foundation, and the Schuman and Pedersen families. ASTOR participates in the ATHENA and Study of RG-012 in Male Subjects With Alport Syndrome (HERA) studies sponsored by Regulus Therapeutics and the Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome (CARDINAL) study sponsored by Reata Pharmaceuticals and receives research support from Novartis Institute for Biomedical Research.

Publisher Copyright:
© 2018 International Society of Nephrology

Keywords

Alport syndrome
chronic kidney disease
proteinuria

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.kint.2017.12.018

OpenUrl availability

Full text

Cite this

Kashtan, C. E., Ding, J., Garosi, G., Heidet, L., Massella, L., Nakanishi, K., Nozu, K., Renieri, A., Rheault, M., Wang, F., & Gross, O. (2018). Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. Kidney international, 93(5), 1045-1051. https://doi.org/10.1016/j.kint.2017.12.018

Kashtan, CE, Ding, J, Garosi, G, Heidet, L, Massella, L, Nakanishi, K, Nozu, K, Renieri, A, Rheault, M, Wang, F & Gross, O 2018, 'Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group', Kidney international, vol. 93, no. 5, pp. 1045-1051. https://doi.org/10.1016/j.kint.2017.12.018

@article{d1fbfa6492694715a2af7517f2f8c052,

title = "Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group",

abstract = "Mutations in the genes COL4A3, COL4A4, and COL4A5 affect the synthesis, assembly, deposition, or function of the collagen IV α345 molecule, the major collagenous constituent of the mature mammalian glomerular basement membrane. These mutations are associated with a spectrum of nephropathy, from microscopic hematuria to progressive renal disease leading to ESRD, and with extrarenal manifestations such as sensorineural deafness and ocular anomalies. The existing nomenclature for these conditions is confusing and can delay institution of appropriate nephroprotective therapy. Herein we propose a new classification of genetic disorders of the collagen IV α345 molecule with the goal of improving renal outcomes through regular monitoring and early treatment.",

keywords = "Alport syndrome, chronic kidney disease, proteinuria",

author = "Kashtan, {Clifford E.} and Jie Ding and Guido Garosi and Laurence Heidet and Laura Massella and Koichi Nakanishi and Kandai Nozu and Alessandra Renieri and Michelle Rheault and Fang Wang and Oliver Gross",

note = "Funding Information: The French Alport Registry is supported by the French Association for the Information and Research on Genetic Renal Diseases (AIRG-France), the National database on Rare Diseases (BNDMR; http://www.bndmr.fr ), and the Rare Disease Cohorts (RADICO; http://www.radico.fr/fr/ ) and participates in the ATHENA study sponsored by Regulus Therapeutics. Funding Information: The Italian registry of Alport syndrome is supported by Italian Association of Alport Syndrome (ASAL; www.asalonlus.it ) by donations in favor of Graziano and Marco Laurini and the correlated biobank is within the Telethon Network of Genetics Biobanks (TNGB; project no. GTB12001). Funding Information: The Alport Syndrome Treatments and Outcomes Registry (ASTOR) is supported by the Alport Syndrome Foundation, the Kenneth and Claudia Silverman Family Foundation, and the Schuman and Pedersen families. ASTOR participates in the ATHENA and Study of RG-012 in Male Subjects With Alport Syndrome (HERA) studies sponsored by Regulus Therapeutics and the Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome (CARDINAL) study sponsored by Reata Pharmaceuticals and receives research support from Novartis Institute for Biomedical Research. Publisher Copyright: {\textcopyright} 2018 International Society of Nephrology",

year = "2018",

month = may,

doi = "10.1016/j.kint.2017.12.018",

language = "English (US)",

volume = "93",

pages = "1045--1051",

journal = "Kidney international",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Alport syndrome

T2 - a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group

AU - Kashtan, Clifford E.

AU - Ding, Jie

AU - Garosi, Guido

AU - Heidet, Laurence

AU - Massella, Laura

AU - Nakanishi, Koichi

AU - Nozu, Kandai

AU - Renieri, Alessandra

AU - Rheault, Michelle

AU - Wang, Fang

AU - Gross, Oliver

N1 - Funding Information: The French Alport Registry is supported by the French Association for the Information and Research on Genetic Renal Diseases (AIRG-France), the National database on Rare Diseases (BNDMR; http://www.bndmr.fr ), and the Rare Disease Cohorts (RADICO; http://www.radico.fr/fr/ ) and participates in the ATHENA study sponsored by Regulus Therapeutics. Funding Information: The Italian registry of Alport syndrome is supported by Italian Association of Alport Syndrome (ASAL; www.asalonlus.it ) by donations in favor of Graziano and Marco Laurini and the correlated biobank is within the Telethon Network of Genetics Biobanks (TNGB; project no. GTB12001). Funding Information: The Alport Syndrome Treatments and Outcomes Registry (ASTOR) is supported by the Alport Syndrome Foundation, the Kenneth and Claudia Silverman Family Foundation, and the Schuman and Pedersen families. ASTOR participates in the ATHENA and Study of RG-012 in Male Subjects With Alport Syndrome (HERA) studies sponsored by Regulus Therapeutics and the Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome (CARDINAL) study sponsored by Reata Pharmaceuticals and receives research support from Novartis Institute for Biomedical Research. Publisher Copyright: © 2018 International Society of Nephrology

PY - 2018/5

Y1 - 2018/5

N2 - Mutations in the genes COL4A3, COL4A4, and COL4A5 affect the synthesis, assembly, deposition, or function of the collagen IV α345 molecule, the major collagenous constituent of the mature mammalian glomerular basement membrane. These mutations are associated with a spectrum of nephropathy, from microscopic hematuria to progressive renal disease leading to ESRD, and with extrarenal manifestations such as sensorineural deafness and ocular anomalies. The existing nomenclature for these conditions is confusing and can delay institution of appropriate nephroprotective therapy. Herein we propose a new classification of genetic disorders of the collagen IV α345 molecule with the goal of improving renal outcomes through regular monitoring and early treatment.

AB - Mutations in the genes COL4A3, COL4A4, and COL4A5 affect the synthesis, assembly, deposition, or function of the collagen IV α345 molecule, the major collagenous constituent of the mature mammalian glomerular basement membrane. These mutations are associated with a spectrum of nephropathy, from microscopic hematuria to progressive renal disease leading to ESRD, and with extrarenal manifestations such as sensorineural deafness and ocular anomalies. The existing nomenclature for these conditions is confusing and can delay institution of appropriate nephroprotective therapy. Herein we propose a new classification of genetic disorders of the collagen IV α345 molecule with the goal of improving renal outcomes through regular monitoring and early treatment.

KW - Alport syndrome

KW - chronic kidney disease

KW - proteinuria

UR - http://www.scopus.com/inward/record.url?scp=85043759128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043759128&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2017.12.018

DO - 10.1016/j.kint.2017.12.018

M3 - Article

C2 - 29551517

AN - SCOPUS:85043759128

SN - 0085-2538

VL - 93

SP - 1045

EP - 1051

JO - Kidney international

JF - Kidney international

IS - 5

ER -

Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this